VSM Wealth Advisory’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

VSM Wealth Advisory’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-120	Closed	-$85	–	446
2025 Q3	$85	Hold	120	–	–	﹤0.01%	430
2025 Q2	$134	Hold	120	–	–	﹤0.01%	498
2025 Q1	$151	Hold	120	–	–	﹤0.01%	483
2024 Q4	$272	Buy	+120	New	+$222	﹤0.01%	462

VSM Wealth Advisory's BCLI Position: Q4 2025 in Review

VSM Wealth Advisory sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2025, closing a stake of 120 shares — an estimated $85 sold.

VSM Wealth Advisory first reported a position in BCLI in Q4 2024 and held it in 4 quarters. The position peaked at $272 in Q4 2024. 0 funds tracked by Wall St. Rank hold BCLI as of Q4 2025.

VSM Wealth Advisory reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2025 after selling out during the quarter.
VSM Wealth Advisory sold 120 BRAINSTORM CELL THERAPUTC shares in Q4 2025, an estimated $85.
VSM Wealth Advisory first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2024 and held it in 4 quarters.
VSM Wealth Advisory's BRAINSTORM CELL THERAPUTC position peaked at $272 in Q4 2024.
0 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2025.

Based on VSM Wealth Advisory's 13F filing for Q4 2025, filed 6 Feb 2026.